IceCure Medical (NASDAQ:ICCM) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS

IceCure Medical (NASDAQ:ICCM) issued its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02), Zacks reports. The company had revenue of $1.28 million during the quarter, compared to analyst estimates of $1.30 million. IceCure Medical had a negative return on equity of 243.68% and a negative net margin of 513.95%.

Here are the key takeaways from IceCure Medical’s conference call:

• FDA clearance plus the American Society of Breast Surgeons’ new guideline recommending cryoablation are cited as major adoption catalysts and the company notes ProSense is the first and only FDA?cleared device for breast cancer treatment.
• Management reported record unit sales and a record Q4 (~$1.3M) driving full?year 2025 revenue of $3.4M, with a growing pipeline converting to signed contracts and installations at prominent hospital systems.
• Current reimbursement is under a CPT Category III code (~$4,000 facility payment) and IceCure has applied for transitional pass?through (up to ~$900) and plans a CPT?1 submission for physician payment, which management views as an inflection point if approved.
• The FDA requires a 30?site post?marketing study (majority of sites identified but not all agreements signed), with onboarding expected in 3–6 months and patient enrollment slated to begin late summer, potentially affecting rollout timing.
• International expansion efforts include a Health Canada Class III amendment for patients 60+ (decision expected H2 2026) and progress toward a Japanese submission with partner Terumo, which management says is already boosting global demand.

IceCure Medical Price Performance

Shares of NASDAQ:ICCM opened at $0.67 on Wednesday. IceCure Medical has a 12 month low of $0.54 and a 12 month high of $1.52. The firm has a market capitalization of $45.69 million, a P/E ratio of -2.56 and a beta of 0.29. The company’s fifty day moving average price is $0.63 and its 200 day moving average price is $0.75.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a report on Thursday, January 22nd. Wall Street Zen upgraded IceCure Medical from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $2.64.

Hedge Funds Weigh In On IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Virtu Financial LLC acquired a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 64,524 shares of the company’s stock, valued at approximately $39,000. Virtu Financial LLC owned approximately 0.09% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.